With the advances in the understanding of cranial pain processing that have been made over the last few years it has become clear that cranial vessels have an important role in the expression of vascular pain syndromes such as migraine and cluster headache. Recent data show that specific populations of cerebrovascular sensory nerves are involved in the pathophysiology of these pain syndromes. The present review provides an account of my interpretation of available data on perivascular peptides in the pathogenesis of primary headaches. This includes a detailed description of the human cerebrovascular sensory innervation, the origin, immunocytochemical distribution and ultrastructural features of perivascular nerves and their role in primary headaches.
changes in the cranial blood levels of CGRP indicate activation of the trigeminal system. These levels are normalized by the highly effective triptan antimigraine agents coincident with the relief of the headache. CGRP is released upon trigeminal nerve activation and the changes in peptide levels are also inhibited by triptans.
Activation of the trigeminal nucleus caudalis (TNC) provides the central link to nociception, pain development, and associated symptoms (Fig. 2) . Hypothetically, intense acti-vation of the central pain pathways may involve the superior salivatory nucleus (SSN), resulting in parasympathetic VIP release, and manifestation of additional facial symptoms. This way of connecting known facts may be useful in our further work to explore the neural innervation of the cerebral and extracerebral vessels, which along with pharmacological studies of the transmitters involved may permit both an understanding of the pathogenesis of migraine and an even better treatment design. Sensorimotor Fig. 1 Migraine locus in the brainstem is hypothetically activated and results in a wave of spreading depression over the brain, constricting the cerebral blood vessels. PAG, periaqueductal grey region The trigeminovascular system For many years, morphological studies of the sensory innervation of the cerebral vascular system were based on methylene blue staining and silver impregnation techniques. However, the results obtained were limited due to the fact that staining was inconsistent and did not allow the discrimination of subpopulations. Significant advances have been made in the morphological analysis of presumptive vascular nerve endings by the introduction of electron-microscopic methods. The presence of an unusual abundance of mitochondria within nerve varicosities has been repeatedly shown to be one of the most distinguishing features of the sensory nerve terminals. In rat cerebral arteries, mitochondria-rich nerve varicosities were interpreted as sensory in nature because they could be traced back to myelinated fibers [4, 5] and did not degenerate after sympathetic denervation by removal of the superior cervical ganglion [6] . Presumptive vascular sensory nerve terminals may contain, besides a large number of mitochondria, small clear and/or dense vesicles (30-60 nm in diameter) and large densecored vesicles (80-150 nm in diameter), autophagic vacuoles, pleomorphic dense bodies, lamellated or myelin figures, and large amounts of glycogen-like granules [7] . These nerve terminal varicosities have been postulated to represent nerve specializations for pressure or tension reception based on the structural analogy they share with sensory or baroreceptor nerve terminals [8] . However, the use of immunocytochemical techniques has increased our knowledge on the distribution of sensory nerve fibers supplying the vasculature. To date, the most widely distributed neuropeptides in afferent cerebrovascular nerve fibers are the neurokinins and CGRP [2, 9] .
Neurokinins
Immunohistochemical studies have shown that substance P (SP), which is the best known neurokinin, is present in nerve fibers supplying cerebral vessels of a variety of species including man ( Fig. 3 ) [10] . Although interspecies differences have not been systematically studied, cerebral arteries from guinea pig and cat receive a relatively dense supply of SP-immunoreactive nerve fibers [11, 12] . Porcine cerebral arteries are innervated by a moderate nerve supply and cerebral vessels from humans, rabbits and rats appear to have a relatively sparse distribution of SP-containing nerve fibers. In general, SP immunoreactive nerve fibers are more abundant in anterior vessels of the circle of Willis, such as the anterior cerebral artery. Nerve fibers containing SP immunoreactivity are also associated with cerebral veins.
Retrograde tracing studies have demonstrated that the major source of cerebrovascular SP-containing nerve fibers is the trigeminal [8, 13] , however, some of the perivascular nerve fibers may also originate in the upper cervical dorsal root ganglia [13, 14] . Unilateral excision of the trigeminal ganglion in the cat decreases cerebrovascu- lar SP levels and induces an almost complete loss of SPimmunoreactive nerve fibers in the wall of cerebral arteries [2, 15] . The origin of SP-immunoreactive nerve fibers has been substantiated by using the sensory neurotoxin capsaicin. Systemic capsaicin treatment of guinea pigs leads to a marked loss of SP immunoreactivity in the cerebral vasculature [16] . However, capsaicin does not deplete SP immunoreactivity from rat brain microvessels [17] . This observation, together with the presence of substantial amounts of SP even after division of the trigeminal nerve, has led to the conclusion that while the trigeminal ganglion is the major source of SP in large cerebral arteries, it may not be the exclusive source of this neuropeptide in brain microvessels. For instance, in the dorsal raphe and interpeduncular nucleus, the dendrite processes of central perikarya containing SP immunoreactivity are intimately associated with small cerebral blood vessels [18] . Neurokinin A (NKA)-immunoreactive nerve fibers have a distribution similar to that of SP-containing nerves and are also depleted after capsaicin treatment [19] . Furthermore, NKA is co-localized with SP in cerebrovascular nerve fibers and in cell bodies in the trigeminal ganglion [19] .
Innervation of intracranial circulation

Dorsal root gangl
Calcitonin gene-related peptide CGRP immunoreactivity is present in perivascular nerve fibers supplying the major cerebral arteries and pial arterioles of the cortical surface of several species including man [2, 13, 14, 15, [20] [21] [22] [23] [24] . Marked species and regional variations have been observed in the density of CGRPimmunoreactive cerebrovascular nerve fibers. While cerebral arteries of laboratory animals receive a relatively dense supply of CGRP-immunoreactive nerve fibers, human cerebral vessels are only innervated with a sparse nerve fiber network ( Fig. 3 ). From surgical denervation studies, it appears that the trigeminal ganglion is the only source for the CGRP-containing cerebrovascular innervation [2, 13, 15] . CGRP frequently coexists with SP and NKA in a population of sensory ganglion cells, although the number of CGRP-containing cells exceeds the number of SP/NKAcontaining neurons. CGRP immunoreactivity is often colocalized with SP/NKA immunoreactivity in perivascular nerve fibers supplying rodent and feline cerebral arteries [15, 19, 25] and the human cerebral and temporal arteries [7, 21, 22] . These results are further supported at the ultrastructural level, where the use of double immunogold staining demonstrated that CGRP and SP immunoreactivities are consistently found co-localized in the same large granular vesicles (70-150 nm in diameter) in both sensory neurons of the trigeminal ganglion and in varicosities of perivascular nerve fibers [5, 7] .
PACAP and NOS
Immunochemistry has revealed the occurence of pituitary adenylate cyclase-activating polypeptide (PACAP) in various parts of the sensory system, e.g. dorsal horn of the spinal cord, in cell bodies of spinal and trigeminal ganglia [26-28]. It coexists with SP and CGRP in fibers and ganglia. With in situ hybridization, mRNA for PACAP has been detected in these ganglia [28] [29] [30] . With the use of specific antibodies, my colleagues and I early noted the presence of PACAP immunoreactive nerve fibers in the cat cerebral circulation [31] . In a subsequent study the origin of the PACAP fibers in the rat was traced to the cranial ganglia [30], however, the majority of these reside in the parasympathetic ganglia. In the human trigeminal ganglion, PACAP-containing cell bodies were more numerous than in the laboratory animals, amounting to 15% [32]. Co-localization was seen with CGRP [30]. It is thus likely that PACAP may have a role also in the sensory system.
In the human sensory system there is also expression of nitric oxide synthase (NOS) in a subpopulation of CGRPcontaining cell bodies [32] . The origin and distribution of cerebrovascular nerve fibers containing NOS have been evaluated previously in several species [30, [33] [34] [35] [36] [37] . The perivascular innervation is denser in the rostral part of the circle of Willis as compared to vessels posteriorly located. In the human circle of Willis, the network of NOS-containing fibers is relatively sparse.
It has been proposed that the trigeminal ganglion in the rat harbors a significant population of NOS-containing nerve cell bodies [34] . In the rat up to 40% of the trigeminal cell bodies store CGRP [13, 14] . In functional studies using NOS blockade (L-NAME), we could not reveal any modification of the increase in cerebral blood flow following trigeminal nerve stimulation [38] . On the other hand, the CGRP blocker CGRP 8-37 significantly attenuated trigeminal vasodilatation in situ, demonstrating a role for CGRP in this pathway. Thus, NOS-immunoreactive perivascular nerve fibers in the rostral part of the cerebral circulation originate mainly in the ipsilateral sphenopalatine and otic ganglia with a near complete colocalization of NOS-immunoreactivity with VIP-and PACAPimmunoreactivity. The role of NO in the sensory system is not clear although there is a suggestion that NO may be involved in the pathogenesis of primary headaches [39, 40] .
Neurotransmitters in primary headaches
Trigeminal ganglion stimulation
The trigeminal system provides an important pain-sensitive link in the cranial vasculature. Studies examining what takes place when the sensory pathway is activated in animals have shown that they have no resting tonic influence on regional cerebral blood flow or regional cerebral metabolism [41] and that trigeminal ganglion stimulation increases intracranial blood flow [42] . In humans, unilateral stimulation of the trigeminal ganglion results in increased bilateral cortical blood flow, slightly more on the stimulated site than contralaterally [43] . Patients under treatment for trigeminal neuralgia are, in addition, noted to flush on the side of stimulation. This coincides with the release of CGRP and SP, a response that is interrupted following cessation of stimulation in our studies [44] .
Migraine attacks
The levels of various neuropeptides in patients from the external jugular vein during migraine attacks. The concentrations of neuropeptide Y (a marker for sympathetic activity), VIP (parasympathetic activity) and CGRP or SP (markers for trigeminal activity) were initially measured. There were no changes in peripheral blood levels of any of the peptides (samples from the cubital fossa vein), while a marked increase in jugular vein CGRP was observed during migraine headache ( Fig. 4) [45, 46]. There was no difference between migraine with aura or without aura; both resulted in substantial increases in venous CGRP levels [46, 47] . In addition, a somewhat higher basal level of CGRP was noted in the cubital fossa vein blood also outside the attack [48] .
My view is that the release of CGRP may be due to the fact that the cerebral circulation is mainly innervated by CGRP from the trigeminal ganglion [13] . CGRP seems to be the main transmitter in the trigeminal ganglion and there is a large amount of CGRP-containing nerve fibers around central blood vessels [2, 15, 21] . It is, therefore, inevitable that CGRP plays a major role in nociception. The clinical observations of a release of CGRP during migraine has been confirmed in subsequent studies by others [47] . In addition, following sumatriptan administration, CGRP levels returned to control levels with successful amelioration of the headache [46].
Cluster headache
Cluster headache is a well-described clinical syndrome. Patients with episodic cluster headache, fulfilling the criteria of the International Headache Society (IHS), have been examined during acute spontaneous attacks of headache to determine the release of neuropeptides [49] . During the attacks, the levels of CGRP and VIP were raised in all subjects, while there were no changes in neuropeptide Y (NPY) or SP levels (Fig. 5 ). Treatment with oxygen or subcutaneous sumatriptan promptly normalized the CGRP levels, while administration of an opiate did not alter the peptide levels [49] . Two individuals with migraine symptoms similar to those seen in cluster headache (e.g. nasal congestion and rhinorrhea) also displayed increased levels of VIP, but this was Clinical studies have shown that activation of the trigeminovascular system and the cranial parasympathetic nervous system plays a role in the acute attacks of cluster headache. It was particularly noteworthy that all subjects responded with release of VIP. This is in concert with the facial symptoms of this disorder. The findings agree well with the results of others [52] demonstrating release of CGRP in nitroglycerin-elicited attacks of cluster headache. Fanciullacci et al. [53] observed in another study that nitroglycerin could only elicit an attack of cluster headache with CGRP release if the patient was in a latent period and thus prone to activation. The finding of elevated levels of both CGRP and VIP in the cranial venous blood during the attacks and the cat experiments suggest that there is activation of a brainstem reflex, the afferent arc of which is the trigeminal nerve and the efferent the cranial parasympathetic outflow from the seventh cranial nerve.
Trigeminal neuralgia
When normal individuals were compared with patients with trigeminal neuralgia [44] , there was no difference between the resting levels of neuropeptides in cranial venous outflow. Stimulation of the trigeminal ganglion in conjunction with thermocoagulation caused a marked increase in the blood levels of CGRP and SP, which was associated with unilateral facial flushing. After cessation of the stimulation, the peptide levels returned to normal.
Vasoactive substances may be responsible not only for causing headache but also for causing neurally mediated facial flushing. Local facial stimulation by tapping a painful trigger point of a patient with a 17-year history of intractable left-sided facial pain led to both pain and flushing [54] . This was associated with a marked increase (120%) in CGRP levels during the flushing with no change in SP, NPY or VIP levels. Thus, the CGRP release was linked with unilateral headache also in this subject.
Chronic paroxysmal hemicrania
Chronic paroxysmal hemicrania (CPH) is a relatively wellrecognized syndrome that is defined by the IHS operational diagnostic criteria as frequent short-lasting attacks of unilateral pain usually in the orbital, supra-orbital or temporal regions that may last for 2-45 minutes. The attack frequency may vary but is usually five or moretimes each day. The pain is associated with prominent autonomic symptoms such as conjunctival injection, lacrimation, nasal congestion, rhinorrhoea, ptosis or eyelid edema. According to the diagnostic criteria, the attacks settle rapidly upon treatment with indomethacin. My colleagues and I have studied one such case and observed that, during the pain, the CGRP level rose to 123 pmol/l compared to a level of 41 pmol/l while on indomethacin or in control subjects [44] [45] [46] 49] . The VIP level rose to 32 pmol/l during an attack, dropping to 7 pmol/l upon indomethacin treatment [55] . This case report and accompanying data show that attacks of CPH are characterized by activation of both sensory and parasympathetic cranial nerve fibers. The neuropeptides were at normal levels when the headaches were controlled on indomethacin. Thus, studies of neuropeptide markers in CPH serve as biological markers. The results also illustrate the possibility that different primary headache syndromes share a similar pathophysiology. Future work will help us to further understand the neurobiology of primary headache disorders. 24 
